The U.S. Food and Drug Administration (FDA) and the Center for Disease Control (CDC) lifted restrictions on the single-shot Johnson & Johnson vaccination for COVID-19 this past Friday (April 23) after the FDA’s Advisory Committee on Immunization Practices (ACIP) met for a secondary meeting to discuss the data associated with the vaccine. Initially, on April 13, the FDA and CDC called for a pause in distribution of the J&J vaccine due to six cases of “rare and severe” type of blood clot called cerebral venous sinus thrombosis (CVST), which later was updated to 15 cases out of 8 million vaccinations, including three fatalities. The FDA acting commissioner, Janet Woodcock, said in a statement on April 23, “Both agencies have full confidence that this vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 years and older.”

Read more here.

More on: